kr1,838.00
0.08% today
Copenhagen, Oct 31, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB

Genmab A/S Stock price

kr1,838.00
-89.50 4.64% 1M
+448.00 32.23% 6M
+345.50 23.15% YTD
+303.50 19.78% 1Y
-1,066.00 36.71% 3Y
-343.00 15.73% 5Y
+1,158.00 170.29% 10Y
+1,718.50 1,438.08% 20Y
Copenhagen, Closing price Fri, Oct 31 2025
-1.50 0.08%
ISIN
DK0010272202
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
kr114.4b
Enterprise Value
kr111.7b
Net debt
positive
Cash
kr2.9b
Shares outstanding
61.5m
Valuation (TTM | estimate)
P/E
90.0 | 110.2
P/S
33.9 | 30.8
EV/Sales
33.1 | 30.1
EV/FCF
116.2
P/B
21.6
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
20.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr3.4b | kr3.7b
EBITDA
kr1.2b | kr1.4b
EBIT
kr1.2b | kr1.2b
Net Income
kr1.3b | kr1.0b
Free Cash Flow
kr961.3m
Growth (TTM | estimate)
Revenue
22.8% | 18.9%
EBITDA
38.1% | 28.9%
EBIT
34.9% | 21.1%
Net Income
58.7% | -9.8%
Free Cash Flow
1.7%
Margin (TTM | estimate)
Gross
94.5%
EBITDA
36.7% | 37.2%
EBIT
34.8%
Net
37.5% | 27.6%
Free Cash Flow
28.5%
More
EPS
kr20.4
FCF per Share
kr15.6
Short interest
-
Employees
3k
Rev per Employee
kr1.2m
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

18x Buy
69%
7x Hold
27%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

Buy
69%
Hold
27%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,377 3,377
23% 23%
100%
- Direct Costs 187 187
115% 115%
6%
3,190 3,190
20% 20%
94%
- Selling and Administrative Expenses 576 576
13% 13%
17%
- Research and Development Expense 1,440 1,440
12% 12%
43%
1,238 1,238
38% 38%
37%
- Depreciation and Amortization 65 65
141% 141%
2%
EBIT (Operating Income) EBIT 1,173 1,173
35% 35%
35%
Net Profit 1,267 1,267
59% 59%
38%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today